Paclitaxel for platinum-refractory ovarian cancer

Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Edward Trimble, J. D. Adams, D. Vena, M. J. Hawkins, M. A. Friedman, J. S. Fisherman, M. C. Christian, R. Canetta, N. Onetto, R. Hayn, S. G. Arbuck

Research output: Contribution to journalArticle

Abstract

Purpose: To provide an investigational drug, paclitaxel, now commercially available, to women with refractory ovarian cancer and to evaluate response and toxicity in these patients. Patients and Methods: Patients with platinum- refractory ovarian cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3, at least three prior chemotherapy regimens, adequate hepatic and renal function, and no significant cardiac history were eligible. Patients were treated with paclitaxel 135 mg/m2 administered by 24-hour continuous intravenous infusion every 3 weeks. Results: Leukopenia was the most frequent toxicity, with 78% of patients experiencing grade 3 or 4 toxicity. Other grade 3 and 4 toxicities were less common: fever (33%), infection (12%), thrombocytopenia (8%), vomiting (7%), cardiac (2%), neurologic (2%), and mucositis (1%). Fifteen treatment-related deaths (1.5%) were reported. The objective response rate was 22% (4% complete response [CR], 18% partial response; 95% confidence interval [Cl] for overall response, 19% to 25%). The median time to progression from treatment initiation was 7.1 months in responding patients and 4.5 months for all patients. The median survival duration was 8.8 months. Conclusion: Paclitaxel has shown activity in women with platinum-refractory ovarian cancer, and it can be administered with an acceptable safety profile. Further research is needed to determine the optimal role of paclitaxel in the primary and salvage treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)2405-2410
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number12
StatePublished - 1993
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Paclitaxel
Platinum
Ovarian Neoplasms
Referral and Consultation
Therapeutics
Investigational Drugs
Salvage Therapy
Mucositis
Leukopenia
Intravenous Infusions
Thrombocytopenia
Nervous System
Vomiting
Fever
History
Confidence Intervals
Kidney
Safety
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Paclitaxel for platinum-refractory ovarian cancer : Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. / Trimble, Edward; Adams, J. D.; Vena, D.; Hawkins, M. J.; Friedman, M. A.; Fisherman, J. S.; Christian, M. C.; Canetta, R.; Onetto, N.; Hayn, R.; Arbuck, S. G.

In: Journal of Clinical Oncology, Vol. 11, No. 12, 1993, p. 2405-2410.

Research output: Contribution to journalArticle

Trimble, E, Adams, JD, Vena, D, Hawkins, MJ, Friedman, MA, Fisherman, JS, Christian, MC, Canetta, R, Onetto, N, Hayn, R & Arbuck, SG 1993, 'Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103', Journal of Clinical Oncology, vol. 11, no. 12, pp. 2405-2410.
Trimble, Edward ; Adams, J. D. ; Vena, D. ; Hawkins, M. J. ; Friedman, M. A. ; Fisherman, J. S. ; Christian, M. C. ; Canetta, R. ; Onetto, N. ; Hayn, R. ; Arbuck, S. G. / Paclitaxel for platinum-refractory ovarian cancer : Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 12. pp. 2405-2410.
@article{9239ac97eebf496ab26d73d97707d03d,
title = "Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103",
abstract = "Purpose: To provide an investigational drug, paclitaxel, now commercially available, to women with refractory ovarian cancer and to evaluate response and toxicity in these patients. Patients and Methods: Patients with platinum- refractory ovarian cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3, at least three prior chemotherapy regimens, adequate hepatic and renal function, and no significant cardiac history were eligible. Patients were treated with paclitaxel 135 mg/m2 administered by 24-hour continuous intravenous infusion every 3 weeks. Results: Leukopenia was the most frequent toxicity, with 78{\%} of patients experiencing grade 3 or 4 toxicity. Other grade 3 and 4 toxicities were less common: fever (33{\%}), infection (12{\%}), thrombocytopenia (8{\%}), vomiting (7{\%}), cardiac (2{\%}), neurologic (2{\%}), and mucositis (1{\%}). Fifteen treatment-related deaths (1.5{\%}) were reported. The objective response rate was 22{\%} (4{\%} complete response [CR], 18{\%} partial response; 95{\%} confidence interval [Cl] for overall response, 19{\%} to 25{\%}). The median time to progression from treatment initiation was 7.1 months in responding patients and 4.5 months for all patients. The median survival duration was 8.8 months. Conclusion: Paclitaxel has shown activity in women with platinum-refractory ovarian cancer, and it can be administered with an acceptable safety profile. Further research is needed to determine the optimal role of paclitaxel in the primary and salvage treatment of ovarian cancer.",
author = "Edward Trimble and Adams, {J. D.} and D. Vena and Hawkins, {M. J.} and Friedman, {M. A.} and Fisherman, {J. S.} and Christian, {M. C.} and R. Canetta and N. Onetto and R. Hayn and Arbuck, {S. G.}",
year = "1993",
language = "English (US)",
volume = "11",
pages = "2405--2410",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Paclitaxel for platinum-refractory ovarian cancer

T2 - Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

AU - Trimble, Edward

AU - Adams, J. D.

AU - Vena, D.

AU - Hawkins, M. J.

AU - Friedman, M. A.

AU - Fisherman, J. S.

AU - Christian, M. C.

AU - Canetta, R.

AU - Onetto, N.

AU - Hayn, R.

AU - Arbuck, S. G.

PY - 1993

Y1 - 1993

N2 - Purpose: To provide an investigational drug, paclitaxel, now commercially available, to women with refractory ovarian cancer and to evaluate response and toxicity in these patients. Patients and Methods: Patients with platinum- refractory ovarian cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3, at least three prior chemotherapy regimens, adequate hepatic and renal function, and no significant cardiac history were eligible. Patients were treated with paclitaxel 135 mg/m2 administered by 24-hour continuous intravenous infusion every 3 weeks. Results: Leukopenia was the most frequent toxicity, with 78% of patients experiencing grade 3 or 4 toxicity. Other grade 3 and 4 toxicities were less common: fever (33%), infection (12%), thrombocytopenia (8%), vomiting (7%), cardiac (2%), neurologic (2%), and mucositis (1%). Fifteen treatment-related deaths (1.5%) were reported. The objective response rate was 22% (4% complete response [CR], 18% partial response; 95% confidence interval [Cl] for overall response, 19% to 25%). The median time to progression from treatment initiation was 7.1 months in responding patients and 4.5 months for all patients. The median survival duration was 8.8 months. Conclusion: Paclitaxel has shown activity in women with platinum-refractory ovarian cancer, and it can be administered with an acceptable safety profile. Further research is needed to determine the optimal role of paclitaxel in the primary and salvage treatment of ovarian cancer.

AB - Purpose: To provide an investigational drug, paclitaxel, now commercially available, to women with refractory ovarian cancer and to evaluate response and toxicity in these patients. Patients and Methods: Patients with platinum- refractory ovarian cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3, at least three prior chemotherapy regimens, adequate hepatic and renal function, and no significant cardiac history were eligible. Patients were treated with paclitaxel 135 mg/m2 administered by 24-hour continuous intravenous infusion every 3 weeks. Results: Leukopenia was the most frequent toxicity, with 78% of patients experiencing grade 3 or 4 toxicity. Other grade 3 and 4 toxicities were less common: fever (33%), infection (12%), thrombocytopenia (8%), vomiting (7%), cardiac (2%), neurologic (2%), and mucositis (1%). Fifteen treatment-related deaths (1.5%) were reported. The objective response rate was 22% (4% complete response [CR], 18% partial response; 95% confidence interval [Cl] for overall response, 19% to 25%). The median time to progression from treatment initiation was 7.1 months in responding patients and 4.5 months for all patients. The median survival duration was 8.8 months. Conclusion: Paclitaxel has shown activity in women with platinum-refractory ovarian cancer, and it can be administered with an acceptable safety profile. Further research is needed to determine the optimal role of paclitaxel in the primary and salvage treatment of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027366246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027366246&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 2405

EP - 2410

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -